Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers

@article{Ridtitid2002RifampinMD,
  title={Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers},
  author={W. Ridtitid and M. Wongnawa and W. Mahatthanatrakul and Jarurat Punyo and M. Sunbhanich},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2002},
  volume={72}
}
Praziquantel is extensively metabolized by the hepatic cytochrome P450 (CYP) enzymes. The CYP3A isoforms are likely to be major enzymes responsible for praziquantel metabolism. Rifampin (INN, rifampicin), a potent enzyme inducer of CYP‐mediated metabolism (especially CYP2C9, CYP2C19, and CYP3A4), is known to markedly decrease plasma concentrations and effects of a number coadministered drugs. The aim of this investigation was to study the possible pharmacokinetic interaction between rifampin… Expand
Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers
Background: Praziquantel, a broad‐spectrum anthelminthic, has been reported to undergo extensive first‐pass metabolism by cytochrome P450 (CYP) enzymes in vivo. Ketoconazole, a potent CYP3A4Expand
Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers
TLDR
This data indicates that rifampin, a potent CYP3A inducer, has been known to markedly decrease plasma concentrations of various drugs, which are concomitantly administered during treatment, including risperidone. Expand
Update on Rifampin and Rifabutin Drug Interactions
TLDR
To avoid a decreased therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Expand
Metabolic profiling of praziquantel enantiomers.
TLDR
In silico, in vitro, and in vivo methods revealed the enantioselective metabolic profile of praziquantel, showing that chirality resulted in differences in substrate location and conformation, which likely accounts for the metabolic differences. Expand
In vitro and in vivo human metabolism and pharmacokinetics of S‐ and R‐praziquantel
TLDR
Reanalysis of samples from a human PZQ‐ketoconazole (KTZ) drug‐drug interaction pharmacokinetic study confirmed that KTZ, a potent inhibitor of CYP3A, selectively increased area under the curve of S‐PzQ by 68% and that of R‐PZQ by just 9%. Expand
The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer).
TLDR
This article presents available data on the chemistry, pharmacokinetics and pharmacodynamics of praziquantel, as well as R-praziquanel, and points to gaps in the authors' knowledge. Expand
Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir
TLDR
Using PZQ in HIV patients needs investigation, as there is a risk of both treatment failure and adverse effects because of induction and inhibition, respectively. Expand
Modulation of expression and activity of cytochrome P450s and alteration of praziquantel kinetics during murine schistosomiasis.
TLDR
It can be concluded that schistosomiasis down-modulated CYP expression and activity and delayed PZQ clearance on PID 55, when a great number of parasite eggs were lodged in the liver. Expand
Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin
TLDR
Both dynamic and static mechanistic models are instrumental in delineating the quantitative contribution of transport and metabolism in the dosing time–dependent repaglinide-rifampicin interactions. Expand
Antiprotozoal and Anthelmintic Agents
TLDR
The potential for interaction between antiparasitics and antiretroviral drugs as there is extensive overlap in patient populations likely infected with both malaria and HIV, which may lead to increased probability of polypharmacy and drug interactions. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 29 REFERENCES
Effect of Rifampin on Plasma Concentrations of Mefloquine in Healthy Volunteers
TLDR
The aim was to study the effect of rifampin on the pharmacokinetics of me floquine, and explore a possible role of CYP3A4 on mefloquine metabolism. Expand
Triazolam is ineffective in patients taking rifampin
TLDR
Rifampin (rifampicin) is a potent inducer of CYP3A4 and it is known to markedly reduce plasma concentrations and effects of drugs such as midazolam. Expand
The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron
TLDR
This work examined the possible effect of rifampin on the pharmacokinetics of orally and intravenously administered ondansetron. Expand
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
Midazolam is a short‐acting benzodiazepine that is metabolized by CYP3A enzymes. Rifampin is a potent enzyme inducer that may seriously interact with some substrates of CYP3A4.
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
TLDR
Data indicate that prehepatic metabolism of verapamil (presumably in the gut wall) is preferentially induced compared with hepatic metabolism and that stereoselectivity of verAPamil metabolism is affected by induction. Expand
Characterisation of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors.
TLDR
Microsomes from phenobarbitone (PB)-pretreated rats metabolised PZQ to its major metabolite 4OH-praziquantel (4OH-PZQ) at a greater rate than those from 20-methylcholanthrene (MC) and saline (SA) pretreated rats, indicating that PZZ is metabolised by PB-inducible isoforms of P450. Expand
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin
Rifampin (INN, rifampicin) is a potent inducer of cytochrome P450 (CYP) enzymes involved in drug metabolism and therefore causes many drug interactions.
Pharmacokinetic Drug Interactions with Rifampicin
TLDR
Clinicians must check the dosages of any accompanying medications with which rifampicin may potentially interact, and monitoring of clinical response and blood drug concentrations is essential to adjust the drug dosage during rifampsicin therapy. Expand
Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease.
TLDR
The results indicate that the side effects and bioavailability of praziquantel are increased in the presence of liver disease. Expand
Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction
TLDR
The pharmacokinetics of cyclosporine was studied in six healthy volunteers after administration of the drug orally and intravenously with and without concomitant rifampin administration to a greater extent than would be predicted by the increased metabolism. Expand
...
1
2
3
...